144 related articles for article (PubMed ID: 33506449)
1. Gastric NET Subtypes: Do We Need An Additional One?
Lock G; Oelckers M; Clauditz TS; Schrader J
Z Gastroenterol; 2021 Mar; 59(3):255-258. PubMed ID: 33506449
[TBL] [Abstract][Full Text] [Related]
2. Gastric neuroendocrine neoplasms and proton pump inhibitors: fact or coincidence?
Cavalcoli F; Zilli A; Conte D; Ciafardini C; Massironi S
Scand J Gastroenterol; 2015; 50(11):1397-403. PubMed ID: 26059834
[TBL] [Abstract][Full Text] [Related]
3. A gastric neuroendocrine tumor after prolonged use of proton pump inhibitors.
Prado PHT; Paula RV; de Faria ATR; Silva BL; Ardengh JC
Rev Esp Enferm Dig; 2023 Apr; 115(4):209-210. PubMed ID: 36148661
[TBL] [Abstract][Full Text] [Related]
4. Gastric neuroendocrine tumours from long-term proton pump inhibitor users are indolent tumours with good prognosis.
Trinh VQ; Shi C; Ma C
Histopathology; 2020 Dec; 77(6):865-876. PubMed ID: 32702178
[TBL] [Abstract][Full Text] [Related]
5. Safety of proton pump inhibitors and risk of gastric cancers: review of literature and pathophysiological mechanisms.
Ko Y; Tang J; Sanagapalli S; Kim BS; Leong RW
Expert Opin Drug Saf; 2016 Jan; 15(1):53-63. PubMed ID: 26560097
[TBL] [Abstract][Full Text] [Related]
6. Netazepide Inhibits Expression of Pappalysin 2 in Type 1 Gastric Neuroendocrine Tumors.
Lloyd KA; Parsons BN; Burkitt MD; Moore AR; Papoutsopoulou S; Boyce M; Duckworth CA; Exarchou K; Howes N; Rainbow L; Fang Y; Oxvig C; Dodd S; Varro A; Hall N; Pritchard DM
Cell Mol Gastroenterol Hepatol; 2020; 10(1):113-132. PubMed ID: 32004755
[TBL] [Abstract][Full Text] [Related]
7. Enterochromaffin-like Cell Hyperplasia-Associated Gastric Neuroendocrine Tumors May Arise in the Setting of Proton Pump Inhibitor Use.
Rais R; Trikalinos NA; Liu J; Chatterjee D
Arch Pathol Lab Med; 2022 Mar; 146(3):366-371. PubMed ID: 34283890
[TBL] [Abstract][Full Text] [Related]
8. Gastric neuroendocrine carcinoma after long-term use of proton pump inhibitor.
Jianu CS; Lange OJ; Viset T; Qvigstad G; Martinsen TC; Fougner R; Kleveland PM; Fossmark R; Hauso Ø; Waldum HL
Scand J Gastroenterol; 2012 Jan; 47(1):64-7. PubMed ID: 22087794
[TBL] [Abstract][Full Text] [Related]
9. Problems Associated with Deprescribing of Proton Pump Inhibitors.
Helgadottir H; Bjornsson ES
Int J Mol Sci; 2019 Nov; 20(21):. PubMed ID: 31684070
[TBL] [Abstract][Full Text] [Related]
10. Systematic review: the effects of long-term proton pump inhibitor use on serum gastrin levels and gastric histology.
Lundell L; Vieth M; Gibson F; Nagy P; Kahrilas PJ
Aliment Pharmacol Ther; 2015 Sep; 42(6):649-63. PubMed ID: 26177572
[TBL] [Abstract][Full Text] [Related]
11. The First Case of Gastric Neuroendocrine Tumors Induced by a Proton Pump Inhibitor in von Hippel-Lindau Disease.
Kawaguchi K; Yashima K; Ikebuchi Y; Yoshida A; Kuwamoto S; Isomoto H
Intern Med; 2022 Sep; 61(17):2587-2592. PubMed ID: 35135919
[TBL] [Abstract][Full Text] [Related]
12. Gastric carcinoids after long-term use of a proton pump inhibitor.
Jianu CS; Fossmark R; Viset T; Qvigstad G; Sørdal O; Mårvik R; Waldum HL
Aliment Pharmacol Ther; 2012 Oct; 36(7):644-9. PubMed ID: 22861200
[TBL] [Abstract][Full Text] [Related]
13. Gastric corpus polyps associated with Proton Pump Inhibitors therapy.
Yakoob J; Abbas Z; Jafri W; Ahmad Z
J Coll Physicians Surg Pak; 2008 Mar; 18(3):172-3. PubMed ID: 18460247
[TBL] [Abstract][Full Text] [Related]
14. Proton Pump Inhibitor Use, Hypergastrinemia, and Gastric Carcinoids-What Is the Relationship?
McCarthy DM
Int J Mol Sci; 2020 Jan; 21(2):. PubMed ID: 31963924
[TBL] [Abstract][Full Text] [Related]
15. Defining prognostic parameters of well-differentiated gastric neuroendocrine tumors based on metastatic potential: a two-center experience.
Kurtulan O; Turhan N; Gedikoğlu G; Akyol A; Sökmensüer C
Acta Gastroenterol Belg; 2022; 85(2):339-345. PubMed ID: 35709778
[TBL] [Abstract][Full Text] [Related]
16. CEA Level, Radical Surgery, CD56 and CgA Expression Are Prognostic Factors for Patients With Locoregional Gastrin-Independent GNET.
Li Y; Bi X; Zhao J; Huang Z; Zhou J; Li Z; Zhang Y; Li M; Chen X; Hu X; Chi Y; Zhao D; Zhao H; Cai J
Medicine (Baltimore); 2016 May; 95(18):e3567. PubMed ID: 27149478
[TBL] [Abstract][Full Text] [Related]
17. A 15-year experience with gastric neuroendocrine tumors: Does type make a difference?
Postlewait LM; Baptiste GG; Ethun CG; Le N; Cardona K; Russell MC; Willingham FF; Kooby DA; Staley CA; Maithel SK
J Surg Oncol; 2016 Oct; 114(5):576-580. PubMed ID: 27393718
[TBL] [Abstract][Full Text] [Related]
18. Insights into Effects/Risks of Chronic Hypergastrinemia and Lifelong PPI Treatment in Man Based on Studies of Patients with Zollinger-Ellison Syndrome.
Lee L; Ramos-Alvarez I; Ito T; Jensen RT
Int J Mol Sci; 2019 Oct; 20(20):. PubMed ID: 31623145
[TBL] [Abstract][Full Text] [Related]
19. Proton-pump inhibitor-induced fundic gland polyps with hematemesis.
Tanaka M; Kataoka H; Yagi T
Clin J Gastroenterol; 2019 Apr; 12(2):193-195. PubMed ID: 30251013
[TBL] [Abstract][Full Text] [Related]
20. [Macrocytosis of red blood cells and early arthritis positive for rheumatoid factor such as initial manifestations of a neuroendocrine gastrin-secreting gastric tumor.].
Manzo C; Natale M; Mossetti G; Piscopo A
Recenti Prog Med; 2017 Mar; 108(3):149-151. PubMed ID: 28398409
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
